4,4'-Dipropionyl-diphenylmethan | 20176-48-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4,4'-Dipropionyl-diphenylmethan
• 英文别名: bis-(4-propionyl-phenyl)-methane；Bis-(4-propionyl-phenyl)-methan；1-[4-(4-Propionylbenzyl)phenyl]-1-propanone；1-[4-[(4-propanoylphenyl)methyl]phenyl]propan-1-one
• CAS: 20176-48-1
• 化学式: C₁₉H₂₀O₂
• 分子量: 280.367
• InChiKey: GPKZUYMYXAPFFA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4,4'-Dipropionyl-diphenylmethan 生成 3,3'-(4,4'-methanediyl-di-phenyl)-di-propionic acid
  参考文献：
  名称：

  Macro Rings. VI. The Preparation of Three New Paracyclophanes^1a

  摘要：

  DOI：

  10.1021/ja01646a040
• 作为产物：
  描述：

  二苯基甲烷 、 丙酸酐 在 三氯化铝 作用下， 生成 4,4'-Dipropionyl-diphenylmethan
  参考文献：
  名称：

  Macro Rings. VI. The Preparation of Three New Paracyclophanes^1a

  摘要：

  DOI：

  10.1021/ja01646a040

文献信息

• Lipid A analogues having immunoactivating and anti-tumour activity
  申请人：Sankyo Company Limited

  公开号：EP0437016A2

  公开（公告）日：1991-07-17

  Compounds of formula (I): [in which: R1 is hydroxy, protected hydroxy, fluorine, or -OP(0)(OH)2; R2 and R3 are independently optionally substituted C6 - C20 aliphatic acyl; R4 is hydroxy, protected hydroxy, or -OP(O)(OH)2, where at least one of R1 and R4 is -OP(O)(OH)2; and R5 is hydroxy, protected hydroxy, or fluorine; provided that, except where at least one of R1 and R5 is fluorine, then at least one of R2 and R3 is a substituted C6 - C20 aliphatic acyl having (i) at least one halogen substituent and (ii) at least one of halogen, hydroxy and C6 - C20 aliphatic acyloxy or at least one of R2 and R3 is a substituted C6 - C20 aliphatic acyl which is substituted by at least one halogen-substituted C6 - C20 aliphatic carboxylic acyloxy]; have Lipid A-like activity and may be used for the treatment, prophylaxis, diagnosis and support of an animal suffering a disease or disorder arising from a deficiency in the immune system or from a tumor. They may be prepared by phosphorylation of corresponding compounds lacking a phosphoryl group.

  式(I)化合物： 其中R1 是羟基、受保护的羟基、氟或-OP(0)(OH)2；R2 和 R3 独立地是任选取代的 C6 - C20 脂肪族酰基；R4 是羟基、受保护的羟基或-OP(O)(OH)2，其中 R1 和 R4 中至少有一个是-OP(O)(OH)2；R5 是羟基、受保护的羟基或氟；条件是，除非 R1 和 R5 中至少有一个是氟，否则 R2 和 R3 中至少有一个是被取代的 C6 - C20 脂肪族酰基，该酰基具有 (i) 至少一个卤素取代基和 (ii) 卤素、羟基和 C6 - C20 脂肪族酰氧基中的至少一个，或者 R2 和 R3 中至少有一个是被至少一个卤素取代的 C6 - C20 脂肪族羧基酰氧基取代的 C6 - C20 脂肪族酰基]；具有类似脂质 A 的活性，可用于治疗、预防、诊断和支持因免疫系统缺陷或肿瘤引起的疾病或紊乱的动物。它们可以通过对缺乏磷酸基团的相应化合物进行磷酸化来制备。
• METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
  申请人：Ramirez De Molina Ana

  公开号：US20100068302A1

  公开（公告）日：2010-03-18

  The invention relates to compositions comprising an acid ceramidase inhibitor and a choline kinase inhibitor as well as to the uses thereof for the treatment of cancer. The invention also relates to methods for the selection of an individualised therapy of a cancer patient based on the detection of the acid ceramidase levels. Moreover, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent and uses thereof for the treatment of cancer. Finally, the invention also relates to compositions comprising a choline kinase inhibitor and an alkylating agent or a death receptor ligand and uses thereof for the treatment of cancer.
• METHODS FOR TREATMENT AND DIAGNOSIS OF CANCER
  申请人：Lacal Sanjuan Juan Carlos

  公开号：US20110250179A1

  公开（公告）日：2011-10-13

  The present invention relates to methods for the treatment of cancer based on the induction of the choline kinase beta (hereinafter ChoKβ) activity as well as to methods for the design of personalized therapies and for determining the response of an agent capable of inducing choline kinase beta (hereinafter ChoKβ) for the treatment of cancer as well as to methods for determining the prognosis of a patient based on the determination of the ChoKβ expression levels as well as based on the determination of the relationship between the ChoKβ and ChoKα expression levels. Finally, the invention relates to methods for determining the response of a patient who suffers from cancer to ChoKα-inhibiting agents based on the determination of the PEMT and/or ChoKβ expression levels.
• INHIBITORS OF HCV NS5A
  申请人：Li Leping

  公开号：US20120040977A1

  公开（公告）日：2012-02-16

  Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C.
• CROSSLINKING OF PROTEINS AND OTHER ENTITIES VIA CONJUGATES OF ALPHA-HALOACETOPHENONES, BENZYL HALIDES, QUINONES, AND THEIR DERIVATIVES
  申请人：Krantz Alexander

  公开号：US20130165382A1

  公开（公告）日：2013-06-27

  The present invention relates to the formation of conjugates (e.g., protein-protein dimers) using a-halo-acetophenones, benzylic halides, quinones, and related compounds as a conjugating system. The invention also features compositions that include the conjugates described herein, as well as uses of these conjugates in methods of medical treatment.